+1-888-308-5802     
News Contact Us

Hanmi Pharma’s Oraxol receives priority review designation from US FDA

Author : Saipriya Iyer | Published Date : 2020-09-03 

Hanmi Pharmaceuticals, a renowned South Korean pharmaceutical firm, has reportedly announced that its new oral anticancer drug, Oraxol, has been assigned the priority review designation by the United States Food and Drug Administration (US FDA).

Speaking on the same, Athenex, partner of Hanmi stated that with the FDA accepting the application review for marketing authorization to treat NDA (metastatic breast cancer), priority review was designated to Axol.

The ‘Priority Review’ system of the FDA decides whether to approve new drugs or not in less than 6 months. It is reserved for drugs that can substantially enhance the safety and efficacy in the diagnosis, treatment, and prevention of critical diseases. The normal screening process generally takes 10 months to complete.

In accordance with the PDUFA (Prescription Drug User Fee Act), the FDA aims to finish the AXOL review of marketing authorization by February 2021.

CMO of Athenex, Rudolph Kwan stated that the company is actively working on priority review with the US FDA in order to offer the medication to patients suffering from metastatic breast cancer as early as possible. The firm plans to continue its investments towards expanding the reach and use of the oral drug.

The review application for Axol was submitted on the basis of outcomes of phase 3 clinical trial in comparison with the efficacy and safety monotherapy and paclitaxel monotherapy in patients diagnosed with metastatic breast cancer. The trial’s primary endpoint, objective response rate (ORR), was enhanced to a significant point in Rexol in comparison with the intravenous paclitaxel, as well as the neuropathy incidence was also relatively low.

Hanmi Pharma’s ‘ORASCOVERY’ platform technology, which transforms the anticancer drugs used for injections to be used for oral therapy was implemented for AXOL. In 2018, Rexol was given the designation of the orphan drug to treat hemangiosarcoma by the FDA. The drug was also approved by European EMA in 2019 to treat soft tissue sarcoma.

Source credit: https://www.en24news.com/2020/09/fda-designates-hanmi-pharmaceuticals-anticancer-drugorasol-for-priority-review.html

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Adobe plans new hiring spree as the company hits record revenues

Published Date: 2020-09-17         Author: Saipriya Iyer

As the COVID-19 pandemic continues to impact the global business landscape, software companies and tech firms seem to be faring much better than other enterprises owing to their compatibility with the work-from-home trend, which ensures employee safety and smooth working of the organization. With ot... Read More

UK housing industry at its four year high according to estate agents

Published Date: 2020-09-11         Author: Saipriya Iyer

Stamp duty cuts and an upsurge in the demand for homes having gardens during the pandemic, has reportedly fueled the housing industry to its highest in the past four years, as per the estate agents and surveyors. Over 44% members of RICS’ (Royal Institute of Chartered Surveyors) have regist... Read More

Sydney share-trading firm Superhero secures over $8 million in capital

Published Date: 2020-09-07         Author: Saipriya Iyer

Superhero, an emerging Sydney-based share trading startup, has reportedly made its entry into the market with over $8 million in capital secured from some of Australia’s largest tech firms. The $8 million investment round was led by the chief and founder of BNPL fintech firm, Zip, Larry Dia... Read More

© 2020 Fractovia. All Rights Reserved